Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease
Vandita Y Mattoo, Chamara Basnayake, William R Connell, Nik Ding, Michael A Kamm, Mark Lust, Ola Niewiadomski, Alexander Thompson, Emily K Wright
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | WILEY | Published : 2021
BACKGROUND: Loss of response to anti-TNF agents is a common clinical problem. Dose escalation may be effective for reestablishing clinical response in Crohn's disease (CD). AIMS: To perform a systematic review assessing the efficacy of escalated maintenance anti-TNF therapy in CD. METHODS: EMBASE, MEDLINE, Web of Science, and CENTRAL databases were searched for English language publications through to April 25, 2021. Full-text articles evaluating escalated maintenance treatment (infliximab or adalimumab) in adult CD patients were included. RESULTS: A total of 4733 records were identified, and 68 articles met eligibility criteria. Rates of clinical response (33%-100%) and remission (15%-83%) ..View full abstract
Declaration of personal interests: VYM, CB, WRC, ND, ML, ON, and AT have no conflicts of interest to declare. MAK has acted as an advisor to AbbVie and Janssen, has received research support from AbbVie, and has acted as a speaker at symposiums sponsored by AbbVie and Janssen. EKW has acted as an advisor to AbbVie, has received research support from AbbVie and Janssen, and has acted as a speaker at symposiums sponsored by AbbVie, Janssen, Dr Falk Pharma and Pfizer.